Nimotuzumab added to standard treatment after glioblastoma surgery
Official title: Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on .
The short version
This study is testing a drug called nimotuzumab alongside the usual treatment given after brain tumor surgery.
Read our full plain-language summary
What the trial team says
This is a prospective, single-arm study. The study population consists of adult patients with a confirmed diagnosis of EGFR-positive high-grade glioma who have radiographic residual tumor following surgical resection. Participants will receive nimotuzumab in combination with the standard Stupp regimen after glioma surgery.
Key facts
- Registry number
- NCT07707973
- Stage of testing
- Phase 2
- Conditions studied
- Glioma, Malignant
Where it is running
No locations are listed for this trial. The trial's own page may have more.
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.